AI Article Synopsis

  • - Lung cancer remains the top cause of cancer deaths globally with a low 5-year survival rate, but the introduction of immune checkpoint inhibitors (ICIs) like nivolumab in 2015 has improved patient survival rates and treatment strategies for non-small cell lung cancer (NSCLC).
  • - An analysis of the Netherlands Cancer Registry from 2016-2020 reveals a dramatic increase in ICI usage from 1.1% to 54.9% among first-line NSCLC patients, with trends indicating a shift away from chemotherapy, though survival rates varied and showed some decline in recent years.
  • - The study highlights that the median overall survival (OS) was different based on treatment lines: first-line patients had a

Article Abstract

Background: Lung cancer is the leading cause of cancer mortality globally, with a 5-year survival rate of 10-20%. In recent years, immune checkpoint inhibitors (ICIs) have significantly improved overall survival (OS) in patients with lung cancer. The approval of nivolumab in 2015 marked a milestone in non-small cell lung cancer (NSCLC) treatment, leading to ongoing trials and approvals of new ICI drugs that have reshaped treatment strategies and clinical outcomes for patients with lung cancer. This study aims to describe ICIs prescription trends for NSCLC in the Netherlands and their association with survival. We compared our results with data from randomized controlled trials (RCTs).

Methods: We analyzed ICIs prescription trends and their relationship with survival using national-level data from the Netherlands Cancer Registry (NCR) for first-line treatments from 2016-2020. Additionally, we performed a secondary analysis using data from the Oncological Life Study (OncoLifeS) for any-line treatments. Descriptive statistics and annual percentage change (APC) assessed trends in patient and treatment characteristics. OS analyses were performed.

Results: In the Netherlands (2016-2020), the proportion of first-line ICI-treated NSCLC patients significantly increased from 1.1% to 54.9% (APC =14.5%, P=0.002), replacing chemotherapy monotherapy. Stage III ICI-treated patients' proportion increased (APC =3.5%, P=0.034), while the proportion of ICI-treated patients with ≥50% programmed death-ligand 1 (PD-L1) expression decreased (APC =-13.82%, P=0.04). Two-year OS was 25.9%. Median OS remained stable, increasing from 2016 to 2018 (16.6 to 19.4 months) and declining slightly in 2019 and 2020 (17.3 and 16.6 months, respectively). In the secondary analysis, median OS varied by treatment line, being 18.8, 9.4 and 7.5 months for first-, second- and third-line treated patients respectively.

Conclusions: Using real-world data, we determined that ICI-based therapies replaced chemotherapy-only schemes as first-line treatment for NSCLC. Our survival data are comparable with data from RCTs on first-line ICI-treated NSCLC. Median OS of ICI treated patients has remained stable, with small decreases in recent years possibly attributed to the proportional decrease of individuals with high PD-L1 expressions in treatment regimens. Further-line treatments are associated with lower survival.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11484730PMC
http://dx.doi.org/10.21037/tlcr-24-264DOI Listing

Publication Analysis

Top Keywords

lung cancer
20
immune checkpoint
8
checkpoint inhibitors
8
non-small cell
8
cell lung
8
cancer
8
cancer registry
8
patients lung
8
icis prescription
8
prescription trends
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!